Concepedia

Alcee Jumonville

AJ

Statistics

Publications

8

Citations

329

H-Index

8

Active since

2005

Affiliations

Gundersen Health System(Current)

University of Wisconsin–Green Bay

University of Wisconsin–Madison

University of Wisconsin Carbone Cancer Center

Aspirus Wausau Hospital

Alcee Jumonville is an author at Gundersen Health System specializing in medicine, pharmacology, and oncology.

Publications per year

2005–2014

8

Publications

8

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

Howard H. Bailey, Steven Attia, Richard R. Love et al. · Cancer Chemotherapy and Pharmacology · 2007 · 71 citations

, , +9

Survivorship care plans: Is there buy‐in from community oncology providers?

Talya Salz, Mary S. McCabe, Erin E. Onstad et al. · Cancer · 2013 · 69 citations · Full text

, , +13

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Amanda F. Cashen, Mark Juckett, Alcee Jumonville et al. · Annals of Hematology · 2011 · 64 citations

, , +15

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

Steven Attia, Jens C. Eickhoff, George Wilding et al. · Clinical Cancer Research · 2008 · 62 citations · Full text

, , +13

A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.

Daniel Frank, Alcee Jumonville, Noelle K. LoConte et al. · PubMed · 2012 · 21 citations · Full text

, , +15

1–5 of 8